August 21, 2006
MANCHESTER, England—Administration of the probiotic Bifantis (Bifidobacterium infantis 35624, from P&G Health) may alleviate symptoms associated with irritable bowel syndrome (IBS), including diarrhea and constipation, according to a new study from the University of Manchester. In the trial, reported in the American Journal of Gastroenterology (101:1581-90, 2006), 362 women between 18 and 65 years of age with diagnosed IBS received placebo or freeze-dried, encapsulated Bifantis once daily for four weeks. At the end of the trial, the probiotic group showed significantly superior results in reducing abdominal pain, bloating, bowel dysfunction, incomplete evacuation, straining and passage of gas; no adverse events were reported. The optimal dosage appeared to be 1x108 cfu.
You May Also Like
Sep 28, 2023
Innovation in stress and sleep management: Holixer™– white paperSep 22, 2023
Cognitive health growth comes out on top: A range of solutions for diverse needs continue to emerge and win – product development guideSep 25, 2023
LifeVantage proxy fight heats up as revenues coolSep 28, 2023
The ashwagandha root production process: Where tradition meets science – article part threeSep 21, 2023